Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01110083 · ClinicalTrials.gov registry record · Phase 1
First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT01110083 is a Phase 1 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 38 participants.
The verdict
NCT01110083, a Phase 1 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
EMD Serono has closed enrollment into this trial prior to determination of maximum tolerated dose (MTD). EMD Serono has decided not to pursue the development of EMD 1204831 in patients with advanced solid tumors for reasons other than safety.
Interventions
- DRUG EMD 1204831
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01110083
The ClinicalTrials.gov registry entry for NCT01110083 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EMD 1204831 is the first listed.
NCT01110083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01110083 about?
NCT01110083 is a clinical study titled "First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors". EMD Serono has closed enrollment into this trial prior to determination of maximum tolerated dose (MTD). EMD Serono has decided not to pursue the development of EMD 1204831 in patients with advanced solid tumors for reasons other than safety.
What is the current status of trial NCT01110083?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2010-04.
What interventions are being tested in trial NCT01110083?
The interventions under investigation include: EMD 1204831 (DRUG).
Who is sponsoring clinical trial NCT01110083?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.